Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Trimmed by Victory Capital Management Inc.

Victory Capital Management Inc. cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 40.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,752,687 shares of the biopharmaceutical company’s stock after selling 1,196,519 shares during the period. Victory Capital Management Inc.’s holdings in Amicus Therapeutics were worth $24,871,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in FOLD. Van ECK Associates Corp boosted its stake in Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 873 shares during the period. Arizona State Retirement System boosted its position in shares of Amicus Therapeutics by 2.0% in the third quarter. Arizona State Retirement System now owns 60,770 shares of the biopharmaceutical company’s stock worth $739,000 after buying an additional 1,213 shares during the period. Rhumbline Advisers grew its holdings in shares of Amicus Therapeutics by 0.3% during the third quarter. Rhumbline Advisers now owns 416,120 shares of the biopharmaceutical company’s stock valued at $5,060,000 after buying an additional 1,372 shares in the last quarter. Profund Advisors LLC raised its position in Amicus Therapeutics by 1.2% during the third quarter. Profund Advisors LLC now owns 122,207 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 1,478 shares during the period. Finally, E Fund Management Co. Ltd. lifted its stake in Amicus Therapeutics by 4.3% in the 3rd quarter. E Fund Management Co. Ltd. now owns 36,377 shares of the biopharmaceutical company’s stock worth $442,000 after acquiring an additional 1,510 shares in the last quarter.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $10.14 on Thursday. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52. Amicus Therapeutics, Inc. has a one year low of $9.70 and a one year high of $14.57. The business’s 50-day moving average price is $11.35 and its two-hundred day moving average price is $11.98. The company has a market capitalization of $3.00 billion, a P/E ratio of -19.88 and a beta of 0.80.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The firm had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. Analysts anticipate that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,928,605.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the transaction, the chief executive officer now directly owns 871,219 shares in the company, valued at approximately $12,197,066. The disclosure for this sale can be found here. Insiders sold 55,208 shares of company stock worth $732,930 over the last ninety days. 2.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

FOLD has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $22.00 target price on shares of Amicus Therapeutics in a research note on Thursday, February 29th. JPMorgan Chase & Co. lowered their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, March 18th.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.